Research Progress of KRAS Mutation in Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of all patients with lung cancer, the majority of patients with lung cancer at the time of diagnosis is in the advanced stage. The development of target therapy based on has c...
Main Authors: | Lei LIU, Suju WEI |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-05-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.05.11 |
Similar Items
-
Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
by: Markus Y. Wu, et al.
Published: (2021-07-01) -
Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation
by: Quan ZHANG, et al.
Published: (2016-05-01) -
Targeting KRAS in Non-Small Cell Lung Cancer
by: Elena Corral de la Fuente, et al.
Published: (2022-01-01) -
Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant
Organ Metastasis in Non-small Cell Lung Cancer
by: Ge GAO, et al.
Published: (2018-07-01) -
Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
by: Radu Pirlog, et al.
Published: (2022-02-01)